Objective:To evaluate the treatment outcome of iron isomaltoside compared with an
oral iron supplement in the management of iron deficiency anemia (IDA). Methods: The study included patients with IDA who visited the Outpatient Clinic of the
Department of Hematology, theAffiliated
Hospital of Qingdao University from October 2021 to August 2022 and met the
inclusion and exclusion criteria. According to the actual application of iron
supplementation, the patients were divided into two groups: iron isomaltoside treatment
group and oral iron treatment group.
Baseline measurements were collected before the start of treatment, and
measurements were collected subsequently at intervals of 1 week, 1 month, and 3
months. The hematological parameters analyzed included
Hemoglobin (Hb), Mean corpuscular hemoglobin (MCH), Mean Hemoglobin content
(MCH), Mean corpuscular Hemoglobin concentration (MCHC), and
Platelet (Plt). Safety data and adverse event profiles were recorded. Results: Intra-group comparisons: After 1 month of treatment, the Hb significantly
improved (P <0.05).
Inter-group comparisons: The biochemical parameters were significantly improved
(P<0.05) in the iron
isomaltoside group compared with those in the oral iron group after 1 month of
iron supplementation in patients with mild and moderate anemia. Adverse
reactions were tolerable for the patients in both iron isomaltoside group and
oral iron group. Only 1 patient in iron isomaltoside group developed
anaphylactic shock during medication and recovered after aggressive rescue. Conclusions: Iron isomaltoside which increases Hb more rapidly compared with the oraliron supplementation has few adverse reactions and
good acceptance.
Chaparro, C.M. and Suchdev, P.S. (2019) Anemia Epidemiology, Pathophysiology, and Etiology in Low-and Middle-Income Countries. Annals of the New York Academy of Sciences, 1450, 15-31. https://doi.org/10.1111/nyas.14092
[3]
Hu, Y.C., Li, M., et al. (2019) Prevalence and Risk Factors for Anemia in Non-pregnant Childbearing Women from the Chinese Fifth National Health and Nutrition Survey. International Journal of Environmental Research and Public Health, 16, Article 1290. https://doi.org/10.3390/ijerph16071290
[4]
National Administration of Disease Prevention and Control (2021) Report on the Status of Nutrition and Chronic Diseases in Chinese Residents (2020). People’s Health Publishing House, Beijing, 38-39.
[5]
Yu, D.M., Zhao, L.Y., et al. (2021) Status of Energy and Primary Nutrients Intake among Chinese Population in 2015-2017. Food and Nutrition in China, 27, 5-10.
[6]
Ling, H. (2012) Iron Deficiency Anemia in China Has Caused a Significant Disease Burden. Fudan University Issued the Current Research Results on the Disease Burden and Diagnosis of Iron Deficiency Anemia in China. China Modern Medicine, No. 32, 1.
[7]
Taki, M., Hasegawa, T., Ninoyu, Y., Mohri, H. and Hirano, S. (2021) Low-Frequency Sensorineural Hearing Loss Associated with Iron-Deficiency Anemia. Journal of International Advanced Otology, 17, 465-467. https://doi.org/10.5152/iao.2021.9369
[8]
Schieffer, K.M., Chuang, C.H., Connor, J., Pawelczyk, J.A. and Sekhar, D.L. (2017) Association of Iron Deficiency Anemia with Hearing Loss in US Adults. JAMA Otolaryngology-Head & Neck Surgeryg, 143, 350-354. https://doi.org/10.1001/jamaoto.2016.3631
[9]
Chung, S.D., Chen, P.Y., Lin, H.C. and Hung, S.H. (2014) Sudden Sensorineural Hearing Loss Associated with Iron-Deficiency Anemia: A Population-Based Study. JAMA Otolaryngology-Head & Neck Surgeryg, 140, 417-422. https://doi.org/10.1001/jamaoto.2014.75
[10]
Hidese, S., Saito, K., Asano, S. and Kunugi, H. (2018) Association between Iron-Deficiency Anemia and Depression: A Web-Based Japanese Investigation. Psychiatry and Clinical Neurosciences, 72, 513-521. https://doi.org/10.1111/pcn.12656
[11]
Moreno-Reyes, R., Corvilain, B., et al. (2021) Iron Deficiency Is a Risk Factor for Thyroid Dysfunction during Pregnancy: A Population-Based Study in Belgium. Thyroid, 31, 1868-1877. https://doi.org/10.1089/thy.2021.0286
[12]
Yao, W.C., Chen, H.J., et al. (2021) The Risk of Fibromyalgia in Patients with Iron Deficiency Anemia: A Nationwide Population-Based Cohort Study. Scientific Reports, 11, Article No. 10496. https://doi.org/10.1038/s41598-021-89842-9
[13]
Hung, S.H., Lin, H.C. and Chung, S.D. (2015) Association between Venous Thromboembolism and Iron-Deficiency Anemia: A Population-Based Study. Blood Coagulation & Fibrinolysis, 26, 368-372. https://doi.org/10.1097/MBC.0000000000000249
[14]
Chang, Y.L., Hung, S.H., et al. (2013) Association between Ischemic Stroke and Iron-Deficiency Anemia: A Population-Based Study. PLOS ONE, 12, e0170872. https://doi.org/10.1371/journal.pone.0170872
[15]
Li, J., Jiang, C., et al. (2022) Association of On-Admission Anemia with 1-Year Mortality in Patients Hospitalized with Acute Heart Failure: Results from the HERO Study. Frontiers in Cardiovascular Medicine, 9, Article ID: 856246. https://doi.org/10.3389/fcvm.2022.856246
DeLoughery, T.G. (2019) Safety of Oral and Intravenous Iron. Acta Haematologica, 142, 8-12. https://doi.org/10.1159/000496966
[18]
Li, L.J. and Zhang, L.S. (2021) Considerations on the Standardized Diagnosis and Treatment of Iron-Deficiency Anemia. National Medical Journal of China, 101, 3266-3270.
[19]
Litton, E., Xiao, J. and Ho, K.M. (2013) Safety and Efficacy of Intravenous Iron Therapy in Reducing the Requirement for Allogeneic Blood Transfusion: A Systematic Review and Meta-Analysis of Randomised Clinical Trials. BMJ, 347, Article f4822. https://doi.org/10.1136/bmj.f4822
[20]
Goodnough, L.T. (2005) Risks of Blood Transfusion. Anesthesiology Clinics of North America, 23, 241-252. https://doi.org/10.1016/j.atc.2004.07.004
[21]
Red Blood Cell Diseases (Anemia) Group, Chinese Society of Hematology, Chinese Medical Association (2019) [Chinese Expert Consensus on the Application of Intravenous Iron (2019)]. Chinese Journal of Hematology, 40, 358-362.
[22]
Rodgers, G.M. and Gilreath, J.A. (2019) The Role of Intravenous Iron in the Treatment of Anemia Associated with Cancer and Chemotherapy. Acta Haematologica, 142, 13-20. https://doi.org/10.1159/000496967
[23]
Jahn, M.R., Andreasen, H.B., et al. (2011) A Comparative Study of the Physicochemical Properties of Iron Isomaltoside 1000 (Monofer), a New Intravenous Iron Preparation and Its Clinical Implications. European Journal of Pharmaceutics and Biopharmaceutics, 78, 480-491. https://doi.org/10.1016/j.ejpb.2011.03.016
[24]
Auerbach, M. and Macdougall, I. (2017) The Available Intravenous Iron Formulations: History, Efficacy, and Toxicology. Hemodialysis International, 21, S83-S92. https://doi.org/10.1111/hdi.12560
[25]
Biggar, P., Leistikow, F. and Walper, A. (2016) A Prospective Observational Study of Effectiveness and Safety of Iron Isomaltoside in Patients with Chronic Renal Failure and Iron Deficiency Anemia. Clinical Nephrology, 86, 310-318. https://doi.org/10.5414/CN108941
[26]
(2009) Platelet and Megakaryocyte Kinetics in Iron Deficiency Anemia. Nutrition Reviews, 32, 276-279. https://doi.org/10.1111/j.1753-4887.1974.tb00974.x
[27]
Elstrott, B.K., Lakshmanan, H.H.S., et al. (2022) Platelet Reactivity and Platelet Count in Women with Iron Deficiency Treated with Intravenous Iron. Research and Practice in Thrombosis and Haemostasis, 6, Article E12692. https://doi.org/10.1002/rth2.12692
[28]
Park, M.-J., Park, P.-W., et al. (2013) The Relationship between Iron Parameters and Platelet Parameters in Women with Iron Deficiency Anemia and Thrombocytosis. Platelets, 24, 348-351. https://doi.org/10.3109/09537104.2012.699641
[29]
Wu, S.L., Zhao, X.D. and Wang, H.Y. (2012) Analysis of the Causes and Treatment Strategies for Primary Treatment of Iron Deficiency Anemia. Chinese Journal of General Practitioners, 11, 618-619.
[30]
Derman, R., Roman, E., et al. (2017) A Randomized Trial of Iron Isomaltoside versus Iron Sucrose in Patients with Iron Deficiency Anemia. American Journal of Hematology, 92, 286-291. https://doi.org/10.1002/ajh.24633
[31]
Schouten, B.J., Hunt, P.J., Livesey, J.H., Frampton, C.M. and Soule, S.G. (2009) FGF23 Elevation and Hypophosphatemia after Intravenous Iron Poly-Maltose: A Prospective Study. The Journal of Clinical Endocrinology & Metabolism, 94, 2332-2337. https://doi.org/10.1210/jc.2008-2396
[32]
Durham, B.H., Joseph, F., Bailey, L.M. and Fraser, W.D. (2007) The Association of Circulating Ferritin with Serum Concentrations of Fibroblast Growth Factor-23 Measured by Three Commercial Assays. Annals of Clinical Biochemistry, 44, 463-466. https://doi.org/10.1258/000456307781646102
[33]
Imel, E.A., Peacock, M., et al. (2011) Iron Modifies Plasma FGF23 Differently in Autosomal Dominant Hypophosphatemic Rickets and Healthy Humans. The Journal of Clinical Endocrinology & Metabolism, 96, 3541-3549. https://doi.org/10.1210/jc.2011-1239
[34]
Shimizu, Y., et al. (2009) Hypophosphatemia Induced by Intravenous Administration of Saccharated Ferric Oxide: Another Form of FGF23-Related Hypophosphatemia. Bone, 45, 814-816. https://doi.org/10.1016/j.bone.2009.06.017
[35]
Kalra, P.A., Bock, K. and Meldal, M. (2012) Iron Isomaltoside 1000: A New High Dose Option for Parenteral Iron Therapy. Portuguese Journal of Nephrology and Hypertension, 26, 13-24.
